MCO® HA technology: controlled crosslinking for professional filler selection
Hyaluronic acid fillers cannot be meaningfully compared by HA concentration or price alone. Crosslinking, gel structure, rheology, cohesivity, particle distribution and injectability together determine a product’s technical profile. Koru Pharma developed MCO® to optimise the reaction between hyaluronic acid and crosslinker under controlled conditions.
MCO® does not automatically make a filler suitable for every patient, indication or technique. It does provide a structured technical framework for comparing Avalon fillers and selecting individual variants professionally.
What is MCO® technology?
MCO® is Koru Pharma’s proprietary crosslinking technology for hyaluronic acid gels. According to the manufacturer, reaction conditions are optimised to support efficient crosslinking, followed by purification and shaping processes that define the final gel profile.
- a controlled degree of crosslinking;
- consistent particle size and gel structure;
- product-specific elasticity and viscosity;
- stable cohesivity;
- consistent extrusion through the supplied needle–syringe combination;
- differentiated gel profiles for professional selection.
Why can this be more relevant than simply choosing ‘more HA’?
A higher HA concentration does not automatically make a filler more appropriate for every application. Material behaviour is determined by the combination of HA concentration, crosslinking, particle structure, elasticity, viscosity and cohesivity. MCO® is therefore most relevant as a process and selection advantage.
Does MCO® mean the product contains no BDDE?
No. BDDE is commonly used to connect hyaluronic acid chains in crosslinked HA fillers. The relevant distinction is not a blanket ‘BDDE-free’ marketing statement, but reaction efficiency, purification processes and any product-specific measured residual values. Q-Global publishes numerical BDDE, endotoxin or purity claims only when supported by an official technical dossier or product-specific analytical report.
Why is MCO® not a guarantee of a better outcome?
An engineered gel profile is only one element of professional use. Outcomes and safety depend on patient selection, anatomy, indication, product choice, injection plan, technique, volume and aftercare. MCO® should therefore be described as an advanced manufacturing and material technology, not as a guarantee of a specific treatment outcome.
Selecting Avalon by gel profile
Compare each SKU by HA concentration, nominal volume, lidocaine content, injection depth stated in the IFU, documented rheology, cohesivity, extrusion force, supplied needle, packaging, batch information and product-specific conformity documentation. The qualified practitioner remains responsible for selecting the product appropriate to the patient, indication, anatomy and technique.
FAQ
Is MCO® a different type of hyaluronic acid?
MCO® is not a separate HA raw material. It is Koru Pharma’s technology for optimising the crosslinking and manufacturing process used to produce HA gels.
Is an MCO® filler automatically better than every other filler?
No. ‘Better’ is meaningful only in relation to a defined criterion, product, indication and professional application. MCO® provides a differentiated technical profile that should be compared with official specifications for alternative products.
Do Avalon fillers contain BDDE?
Crosslinked HA fillers may use BDDE as a crosslinker. Consult the official technical documentation for each Avalon variant for manufacturing information and any measured residual values.
What do rheology and cohesivity mean in dermal fillers?
Rheology describes how a gel deforms and flows under stress. Cohesivity describes how the gel remains integrated as a mass. Both help professionals assess material behaviour alongside HA concentration and crosslinking.
Can Q-Global assist with product selection?
Q-Global can explain specifications and available manufacturer documentation. Indication, patient selection, injection technique and final product choice remain the responsibility of the qualified practitioner.